MX9703582A - Novedoso gene supresor de tumor, hic-1. - Google Patents

Novedoso gene supresor de tumor, hic-1.

Info

Publication number
MX9703582A
MX9703582A MX9703582A MX9703582A MX9703582A MX 9703582 A MX9703582 A MX 9703582A MX 9703582 A MX9703582 A MX 9703582A MX 9703582 A MX9703582 A MX 9703582A MX 9703582 A MX9703582 A MX 9703582A
Authority
MX
Mexico
Prior art keywords
hic
tumor suppressor
novel tumor
suppressor gene
novel
Prior art date
Application number
MX9703582A
Other languages
English (en)
Other versions
MXPA97003582A (es
Inventor
Stephen B Baylin
Michele Makos Wales
Original Assignee
Univ Johns Hopkins Med
Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med, Of Medicine filed Critical Univ Johns Hopkins Med
Publication of MX9703582A publication Critical patent/MX9703582A/es
Publication of MXPA97003582A publication Critical patent/MXPA97003582A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)

Abstract

Se proporcionan secuencias de polinucleotido y polipéptido que codifican un novedoso supresor de tumores HIC-1. También se incluye un método para detectar un desorden proliferativo celular asociado con HIC-1, HIC-1 es un marcador que puede ser usado en forma de diagnostico, pronostico y terapéuticamente el curso de tales desordenes.
MXPA/A/1997/003582A 1994-11-15 1997-05-15 Gene novedoso supresor de tumores, hic-1 MXPA97003582A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/340,203 US5756668A (en) 1994-11-15 1994-11-15 Hypermethylated in cancer polypeptide, HIC-1
US08340203 1994-11-15
PCT/US1995/014996 WO1996014877A1 (en) 1994-11-15 1995-11-15 Novel tumor suppressor gene, hic-1

Publications (2)

Publication Number Publication Date
MX9703582A true MX9703582A (es) 1997-10-31
MXPA97003582A MXPA97003582A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
EP0792168A4 (en) 1999-10-20
KR970706849A (ko) 1997-12-01
JPH10510145A (ja) 1998-10-06
NO972228L (no) 1997-07-14
FI972066A (fi) 1997-07-14
AU4407196A (en) 1996-06-06
WO1996014877A1 (en) 1996-05-23
CA2205414A1 (en) 1996-05-23
EP0792168A1 (en) 1997-09-03
US6103877A (en) 2000-08-15
CN1171743A (zh) 1998-01-28
US5756668A (en) 1998-05-26
FI972066A0 (fi) 1997-05-14
US5922590A (en) 1999-07-13
BR9509674A (pt) 1997-09-16
NO972228D0 (no) 1997-05-14
US5846712A (en) 1998-12-08
NZ298554A (en) 2000-01-28

Similar Documents

Publication Publication Date Title
NZ298554A (en) A tumour suppressor gene (Hypermethylated in Cancer) HIC-1 and its use
PT74811B (en) Bacillus cloning vectors recombinant dna molecules bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby
IL62553A0 (en) Vectors comprising dna sequences and methods for producing recombinant dna molecules and cloning vectors
PH21848A (en) Dna sequences and recombinant dna molecules
HK1066860A1 (en) Human antibodies that bind human tnf alpha
NZ332634A (en) Isolated autophosphorylating polypeptide having phosphoinositide-3-kinase activity
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
GR3033636T3 (en) Dna sequence and encoded mammary-specific breast cancer protein
PT83655B (en) Dna sequences recombinant dna molecules and processes for producing mullerian inhibiting substance-like polypeptides
EP0684955A4 (en) NUCLEAR MATRIX PROTEINS.
TW200716746A (en) Methods for identifying a compound modulating the binding between polypeptides
DK0760010T3 (da) Fremgangsmåder til screening for Crohn's sygdom under anvendelse af TNF-mikrosatellit-alleler
IL92956A0 (en) Gene sequences which encode acylpeptide hydrolase and methods for detecting cancer utilizing the same
DE3366637D1 (en) Treatment agents for molten steel
MX9705025A (es) Proteinas de matriz nuclear de vejiga y su uso para detectar y tratar trastornos proliferativos celulares.
EP0077664A3 (en) Recombinant dna and coliform bacillus having genetic material for the production of staphylokinase, and the production of staphylokinase
AU5615594A (en) Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
EP0324788A4 (en) LAMININE BINDING PEPTIDE FRAGMENTS.
WO2000009526A3 (en) Method for dpc4 (smad4) nuclear localization
GB9905218D0 (en) Neurodegenerative disorder related gene
GB2216127B (en) Modified dna sequences coding for mutant endotoxins of bacillus thuringiensis
AU7300998A (en) Receptor tyrosine kinase genes
AU3941002A (en) Cyp1b1 nucleic acids and methods of use
NZ502270A (en) Derivatives of mammalian secretory peptide-9 for treating cancer and may be used in conjunction with cytokines
CA2347371A1 (en) HEMATOPOIETIC REGULATION FACTORS AND METHODS OF USE

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees